Colombia says no to Kaletra compulsory licence
This article was originally published in Scrip
The Colombian government will not be declaring Abbott's antiretroviral Kaletra (lopinavir plus ritonavir) to be of public interest, leaving the patent on the product intact until 2016. Civil society has accused the government of putting politics first.
Register for our free email digests: